Hematology
News from the FDA/CDC
FDA approves treatment for sickle cell pain crises
Crizanlizumab-tmca (Adakveo) is approved for patients with sickle cell disease who are aged 16 years and older.
Conference Coverage
Thromboembolic events more likely among CIDP patients with CVAD
AUSTIN, TEX. – Although the study matched patients by demographic factors, researchers did not adjust the analysis for risk factors or confounders...
From the Journals
Global blood supply runs low
Worldwide, more than 60% of countries had an inadequate supply of blood to meet the demand for transfusion.
From the Journals
Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APS
Patients who took rivaroxaban experienced almost two times as many thrombotic events as patients who took dose-adjusted vitamin K antagonists.
Feature
Novel research aims to improve ED care in sickle cell disease
Researchers are testing the best acute pain management strategies to respond to a vasoocclusive crisis.
Conference Coverage
Early post-ACS bleeding may signal cancer
PARIS – Cancer risk is elevated with bleeding, whether or not DAPT is employed
From the Journals
Timing, volume of transfusion may not matter in children with severe anemia
The TRACT trial showed no significant differences in 28-day mortality or other clinical outcomes by transfusion timing or volume.
Conference Coverage
Sickle cell unit running 24/7 reduces readmissions, emergency visits
FORT LAUDERDALE, FLA. – An analysis of an around-the-clock sickle cell unit showed significant reductions in per-patient health care utilization...
Conference Coverage
No reduction in PE risk with vena cava filters after severe injury
MELBOURNE – “Given the cost and risks associated with a vena cava filter, our data suggest that there is no urgency to insert the filter in...
News from the FDA/CDC
CDC warns against misuse of opioid-prescribing guideline
Officials at the Centers for Disease Control and Prevention are advising against misapplication of the agency’s guideline on opioid prescribing....
Conference Coverage
Andexanet alfa effectively reverses factor Xa inhibition
HONOLULU – The drug establishes good or excellent hemostasis in 82% of patients with acute major bleeding associated...